Valneva SE (VALN) Amortizatization of Intangibles (2022 - 2026)
Valneva SE's (VALN) quarterly Amortizatization of Intangibles came in at $1.4 million in Q1 2026, up 11.3% year-on-year from $1.3 million in Q1 2025, and up 0.58% quarter-over-quarter from $1.4 million in Q4 2025.
Valneva SE (VALN) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Valneva SE has disclosed Amortizatization of Intangibles across 5 years of filings, most recently posting $1.4 million for Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $1.4 million, up 11.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (up 7.92% YoY), and the FY2025 annual result was $5.6 million, up 6.71% from the prior year.
- Amortizatization of Intangibles came in at $1.4 million for Q1 2026 at Valneva SE, up from $1.4 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $5.3 billion in Q3 2022 to a low of -$5.4 billion in Q4 2022.
- The 5-year median for Amortizatization of Intangibles is $1.4 million (2025), against an average of -$2.7 million.
- Peak annual rise in Amortizatization of Intangibles reached 100.02% in 2023, while the deepest fall reached 99.97% in 2023.
- Valneva SE's Amortizatization of Intangibles stood at -$5.4 billion in 2022, then surged by 100.02% to $1.2 million in 2023, then advanced by 8.35% to $1.3 million in 2024, then increased by 8.93% to $1.4 million in 2025, then advanced by 0.58% to $1.4 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.40 Mn |
| Mar 31, 2026 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 1.28 Mn |
| Dec 31, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Dec 31, 2023 | 1.18 Mn |